Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00385255 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,726
- Enrollment target
NCT00385255 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,726 participants.
The verdict
NCT00385255, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,726 participants
- Enrollment target
Study Summary
The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
Interventions
- BIOLOGICAL Boostrix®
- BIOLOGICAL Fluarix®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,726 participants |
| Start Date | 2006-10-23 |
| Est. Completion | 2007-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00385255
The ClinicalTrials.gov registry entry for NCT00385255 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,726 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Boostrix® is the first listed.
NCT00385255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00385255 about?
NCT00385255 is a clinical study titled "Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults". The current study will provide information for the use of Boostrix concomitantly with influenza vaccine in adults aged 19-64 years. This study will also provide safety and immunogenicity data in a cohort of adults aged greater than or equal to 65 years.
What is the current status of trial NCT00385255?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,726 participants. The study started on 2006-10-23. Estimated completion is 2007-02-28.
What interventions are being tested in trial NCT00385255?
The interventions under investigation include: Boostrix® (BIOLOGICAL), Fluarix® (BIOLOGICAL).
Who is sponsoring clinical trial NCT00385255?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.